Korean health Biotech startup K-BioCELF is a company pioneering the infectious diseases and anticancer treatment, and Diagnosis market with innovative technology. It works in the early detection of cancer for prevention and better treatment.
K-BioCELF’s CELB ACE + ONT system is a liquid biopsy platform technology based on blood cancer cells (CTC; Circulating Tumor Cells). In particular, it has a circulating tumor cell (CTC) separation device technology that can select living cancer cells by grafting the MEMS process, a semiconductor technology. It works in the early detection of cancer for prevention and better treatment.
CELB ACE has a blood cancer cell-based liquid biopsy platform, a personalized platform based on automated cell culture, and a sample separation and automation system. The liquid biopsy technology diagnoses cancer by finding traces of DNA fragments generated when cancer cells break down in human body fluids. It is faster and simpler than tissue biopsy and can be tested using samples from outside the human body.
K-BioCELF is a company founded in 2019 that focuses on diagnostic equipment and advanced biopharmaceuticals, autoimmune disease treatment, anticancer treatment, and bio-production automation equipment (CTC/cell incubator, etc.). Besides CELB ACE, the company also has other products and services like CELP (an artificial skin model production system), CELF (a cell therapy product production system), CELH (a reagent dispensing system), CELH (a microbial inoculation automation system), and a customer automation system.
Also Read,
- Erangtek is making 5G communication better with its frequency interference cancellation solution
- Bumyeong wants manufacturing businesses to achieve sustainability goals with its green-tech solutions
- Apelles’ Electronic Shelf Labelling solution can be operated with a smartphone app
- Gyeonggi Startup Hub Global Accelerating Program 2022 nurtured 10 Korean startups for overseas expansion
